Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity

Elisabet Svenungsson,1,2 Iva Gunnarsson,1,2 Vera Illescas-Bäckelin,1 Estelle Trysberg,3 Andreas Jönsen4,5 Dag Leonard,5 Christopher Sjöwall6, Susanne Pettersson6,2,7

ABSTRACT

Objectives Most indices of disease activity in SLE combine physicians’ assessments and laboratory tests. However, there is also a need to capture patients’ perspectives of disease activity. Consequently, we need new, preferably quick and easy instruments to collect this information, which can be very useful for online consultations and registry purposes. We compared patients’ assessments of SLE disease impact/activity, as reported by a shorter version of the Quick Systemic Lupus Activity Questionnaire (Q-SLAQ), with physicians’ assessments using the Systemic Lupus Activity Questionnaire (SLAQ). Spearman’s ρ correlations were explored between patients’ total Q-SLAQ and subscales (Symptom Score, Patient’s Global Disease Activity and physicians’ SLAM and SLEDAI-2K, with and without laboratory items (SLAM-nobal and SLEDAI-2K-nobal) and SLAQ. Corresponding items in Q-SLAQ and SLAM were compared.

Results Correlations between patients’ and physicians’ assessments were higher for SLAM-nobal (total Q-SLAQ, ρ=0.71; Symptom Score, ρ=0.67; and Patient’s Global Disease Activity, ρ=0.68) than for the original SLAM (total Q-SLAQ, ρ=0.53; Symptom Score, ρ=0.50; and Patient’s Global Disease Activity, ρ=0.53). Regarding specific symptoms, fatigue (ρ=0.72) and alopecia (ρ=0.71) correlated best, while pulmonary/respiratory symptoms correlated least (ρ=0.19, ρ=0.039). Physicians’ assessment with SLEDAI-2K-nobal correlated weakly with patients’ assessments (total Q-SLAQ, ρ=0.30; Symptom Score, ρ=0.30; and Patient’s Global Disease Activity, ρ=0.36). Bivariate correlations between Q-SLAQ and SLAQ were good (ρ=0.82–0.96).

Conclusions Q-SLAQ and the original SLAQ performed equally well, demonstrating that the shorter Q-SLAQ can safely be used to monitor patients’ perception of disease impact/activity. We also noted an intriguing discrepancy between physicians’ and patients’ evaluations of pulmonary/respiratory symptoms, which requires further investigations.

INTRODUCTION

SLE is a chronic inflammatory disease with multiple manifestations. The disease has a variable course where periods of flare-ups and remissions intervene, though some patients also have a more persistently active disease.1 High disease activity, but also side effects of treatments, contributes to significant organ damage over time.2 With the over-reaching goal to prevent organ damage, standardised indices based on more or less time-consuming questionnaires filled out by doctors are used to monitor disease activity and to evaluate treatment in general practice and in clinical trials. However, there is presently no consensus on which questionnaires best reflect disease activity, and knowledge is limited regarding
the role of patient-reported outcome measures (PROMs) in the assessment of SLE disease activity. Continuous research to improve standardised tools to monitor disease activity and treatment outcomes is therefore of major importance in SLE.

The Systemic Lupus Activity Questionnaire (SLAQ) is an extensively translated tool that captures patients’ assessments of SLE-related symptoms and disease activity, with good correlations to physicians’ assessments of SLE disease activity. The SLAQ is constructed to be used in epidemiological studies and aims to capture the multitude of potential organ manifestations of SLE over the last 3 months, resulting in an extensive questionnaire with 26 items for patients to consider and respond to. However, in a recent study, we found that some of the questions in the SLAQ were difficult to answer and had poor correlation to physicians’ assessments of symptom activity. Interestingly, this was most evident for patients with short disease duration. In clinical practice, which nowadays incorporates a growing share of online consultations, it is important to have an ‘easy to fill in’ tool which captures PROMs adequately for the majority of patients. However, to be useful in repeated consultations during disease flares, the instrument should cover a shorter time period than the original SLAQ, which covers the previous 3 months. Such an instrument would also be very valuable for clinical registry purposes. Based on our previous experience, we therefore revised the Swedish version of the SLAQ into a shorter version, which is easy for the patients to answer (Quick Systemic Lupus Activity Questionnaire (Q-SLAQ)).

In the present study, we evaluate the performance of Q-SLAQ in comparison to SLE Activity Measure (SLAM), SLE Disease Activity Index (SLEDAI-2K) and the original SLAQ.

PATIENTS AND METHODS

Patients

Patients with SLE were consecutively included at clinical visits. Since healthcare, including the use of questionnaires, might vary between regional centres, we recruited experienced physicians and patients from five tertiary referral rheumatology specialist centres in Sweden. All participants fulfilled at least four of the American College of Rheumatology criteria for SLE. The patients completed the Q-SLAQ prior to visiting the rheumatology specialist centre for a medical examination. Rheumatologists, who were blinded to the patients’ Q-SLAQ results, filled out SLAM and SLEDAI-2K during the clinical consultation. Additionally, a different set of patients completed both the Q-SLAQ and the Swedish version of the original SLAQ, with or without physicians’ assessments of SLAM according to clinical practice. The patients in the additional data collection were comparable to the first data group, according to age and disease duration.

Questionnaires

The original version of the SLAQ includes 26 items that capture patients’ assessments of SLE-related symptoms and disease activity. The questionnaire has four possible scoring systems: (1) the total SLAQ score grades the severity of 24 symptoms on a scale of 0–47; (2) the Symptom Score is the sum of the non-graded presence (1) or absence (0) of symptoms and is rated on a scale of 0–24; (3) the severity of lupus flare-ups is rated on a scale of 0–3; and (4) the Patients’ Global Disease Activity is rated on a numerical rating scale of 0–10. The translation process from the original SLAQ to the Swedish version of the SLAQ is previously described by Pettersson et al. This version was used for comparison in the additional set of patients. The previous study among Swedish patients showed excellent to good internal consistency (Cronbach’s alpha) of the Symptom Score (0.907) and the SLAQ score (0.862). However, the question of flare-ups seemed to be the most difficult for patients to answer, and additionally, the analyses of Cronbach’s alpha suggested that the removal of the epilepsy symptom item slightly improved the scale. Moreover, the only symptom item with no correlation between the patients’ and the physicians’ assessments, in our previous study, was neurological/stroke syndrome. Based on these results, these two symptom items (epilepsy and neurological/stroke syndrome) were removed as was the question about flare-ups. After discussions with patients’ representative research partners, we added one symptom item, dryness in the mouth and eyes (sicca symptoms). Furthermore, a discussion of clinical relevance was conducted with an executive group of senior rheumatologists with extensive experience working with SLE, and the reduced version of the SLAQ was determined as clinically relevant. Finally, the time frame of the patients’ assessment was decreased from the original 3 to 1 month to be more comparable to the physicians’ assessment of SLAM, to be more useful for clinical consultations during flares and also to improve recall accuracy.

This procedure resulted in a new, revised and tentative version of the Swedish questionnaire, the Q-SLAQ, covering patients’ report of 19 symptom items and one global activity item. Congruent with previous studies, excluding the question of flare-ups, the following three scorings were analysed in the present study. First, the calculation of the Total Q-SLAQ Score was based on the algorithm that was previously developed by Karlson et al. This algorithm converts distress from joints, muscles, lungs and cognitive impairment, each of which were represented by two questions, while three questions deal with skin/mucosal distress combined into one item, respectively. This results in a questionnaire that captures distress from 13 areas (weight loss, fatigue, fever, lymphadenopathy, dryness of the eyes/mouth, myalgia/myositis, arthralgia/arthritis, skin/mucosal, alopecia, pulmonary, abdominal pain, headaches and cognitive dysfunction). Second, the simple calculation of the Q-SLAQ Symptom Score was used, which is the sum of
the non-graded presence regardless of mild, moderate or severe (1) or absence (0) of symptoms among the 19 investigated symptom items. Third, the Patient’s Global Disease Activity was assessed with a single item.

To summarise, the Total Q-SLAQ Score is a summary score on a scale of 0–24; the Symptom Score is a summary score on a scale of 0–19 and the Patient’s Global Disease Activity is scored on a scale of 0–10 (online supplemental). High values indicate greater perceived disease impact/distress.

### Disease activity evaluated by the physicians

In both questionnaires, SLAM and SLEDAI-2K, used by the physicians, high values indicate more disease activity. SLAM covers and grades clinical symptoms and laboratory variables, in nine organ systems during the previous month (score range of 0–83). A SLAM score of 6 or more is considered clinically important and is used as an indication to start medical treatment. The SLEDAI-2K includes presence versus absence of symptoms in nine organ systems represented by 16 clinical and 8 laboratory variables, in nine organ systems during the previous month (score range 0–105). Since the patient’s self-assessment of Q-SLAQ does not include any laboratory variables, we calculated and evaluated SLAM and SLEDAI-2K, with and without laboratory items (SLAM-nolab, score range 0–19; SLEDAI-2K-nolab, score range 0–83).

### Statistics

For statistical calculations, the Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA), version 20 was used. The scales used for the evaluations in this study were primarily ordinal; thus, median, IQR and non-parametric tests were used. A p-value of <0.05 was considered statistically significant. The internal consistency of the Symptom Score (19 items) and the Total Q-SLAQ Score (13 items) was calculated using Cronbach’s alpha. To explore the criterion validity, the relationship between the Q-SLAQ and previously established measurements was assessed. Bivariate correlations with Spearman’s correlations were used to compare the patients’ assessments (Total Q-SLAQ Score, Symptom Score and Patient’s Global Disease Activity) and physicians’ assessments (SLAM, SLAM-nolab, SLEDAI-2K and SLEDAI-2K-nolab) of disease activity; additionally, the individual symptom items from the Q-SLAQ were compared with the corresponding items on SLAM. In the second data collection bivariate correlations with Spearman’s correlations were used to explore the subscales of patients’ assessments of both Q-SLAQ and the Swedish version of SLAQ (Total SLAQ Score, Symptom Score and Patient’s Global Disease Activity). Bivariate correlations for both these questionnaires were also analysed with using only the physicians’ assessments (SLAM-nolab) and not including the laboratory evaluations. The correlation coefficients were evaluated using Colton’s guidelines. The Mann-Whitney U test was used for between-group comparisons.

An overview of the results from Q-SLAQ and previous studies of the original version of SLAQ as well as the Swedish version of SLAQ is presented in the online supplemental material.

### RESULTS

This study analysed 115 paired assessments conducted by both patients and physicians. The patient’s characteristics (87% women) are presented in Table 1. A majority (70%) of the patients had low disease activity as captured by SLAM (≤6). The response rate was ≥95% for all the individual items. Cronbach’s alpha results were 0.905 for the Symptom Score (19 items) and 0.893 for the Total Q-SLAQ Score (13 items). For comparisons, performances of Q-SLAQ and Q-SLAQ were similar cultural context and the original SLAQ are presented in the online supplemental data.

| Characteristics of the 115 participants with SLE (women 87%) |
|-----------------|-----------------|-----------------|
| **Median**     | **IQR**         | **Min–Max**     |
| **Age (years)**| 43              | 32–56           | 18–77           |
| **Disease duration**| 15              | 7–24            | 0–49            |
| **Patients’ assessment** |               |                 |                 |
| Total Q-SLAQ‡  | 10              | 5–17            | 0–35            |
| Symptom Score‡ | 8               | 4–13            | 0–19            |
| Patient’s global disease activity§ | 4               | 1–7             | 0–9             |
| **Physician’s assessment** |               |                 |                 |
| SLAM-nolab     | 3               | 1–6             | 0–14            |
| SLAM           | 4               | 2–9             | 0–19            |
| SLEDAI-2K-nolab| 0               | 0–2             | 0–16            |
| SLEDAI-2K      | 2               | 2–5             | 0–21            |

*M−max indicates range from lowest to highest. †Missing, n=33. ‡Without the sicca symptom. §Missing, n=5. Q-SLAQ, Quick Systemic Lupus Activity Questionnaire; SLAM, SLE Disease Activity Index; SLAM-nolab, Systemic Lupus Activity Measure without laboratory parameters; SLEDAI-2K, SLE Disease Activity Index; SLEDAI-2K-nolab, SLE Disease Activity Index without laboratory parameters.

### Associations between patients’ and physicians’ assessments

Bivariate correlation between the patients’ and physicians’ assessments is described in Table 2. The summary scores (the Total Q-SLAQ Score and the Symptom Score) were explored with and without the new item sicca symptom. Overall, the strongest correlations were observed between the physicians’ assessment using SLAM-nolab and all the scoring results for the Q-SLAQ without the sicca symptom. The strongest correlation was observed between the physicians’ SLAM-nolab and the patients’ Total Q-SLAQ scores (p=0.71, p<0.001). No significant correlations were identified between the patients’ and physicians’ assessments when using SLEDAI-2K (p<0.09 for all).

---

Svenungsson E, et al. Lupus Science & Medicine 2021;8:e000471. doi:10.1136/lupus-2020-000471

---

Lupus Sci Med: first published as 10.1136/lupus-2020-000471 on 10 May 2021. Downloaded from http://lupus.bmj.com/ on September 12, 2023 by guest. Protected by copyright.
had two patient groups. Participants with low disease activity
found that the correlations between patients’ and physi-
ological parameters.

**Table 2** Correlations* between patients’ self-assessment of
SLE disease activity and physician’s assessment (n=115)

| Correlation | Coefficient* | P value |
|-------------|--------------|---------|
| SLAM-nolab versus Total Q-SLAQ | 0.709 | <0.001 |
| SLAM-nolab versus Total Q-SLAQ with sicca | 0.690 | <0.001 |
| SLAM-nolab versus Symptom Score | 0.680 | <0.001 |
| SLAM-nolab versus Symptom Score with sicca | 0.674 | <0.001 |
| SLAM-nolab versus Patient’s global disease activity | 0.683 | <0.001 |

| SLAM versus Total Q-SLAQ | 0.528 | <0.001 |
| SLAM versus Total Q-SLAQ with sicca | 0.505 | <0.001 |
| SLAM versus Symptom Score | 0.496 | <0.001 |
| SLAM versus Symptom Score with sicca | 0.488 | <0.001 |
| SLAM versus Patient’s global disease activity | 0.529 | <0.001 |

| SLEDAI-2K nolab versus Total Q-SLAQ | 0.303 | 0.001 |
| SLEDAI-2K nolab versus Total Q-SLAQ with sicca | 0.274 | 0.004 |
| SLEDAI-2K nolab versus Symptom Score | 0.301 | 0.001 |
| SLEDAI-2K nolab versus Symptom Score with sicca | 0.292 | 0.002 |
| SLEDAI-2K nolab versus Patient’s global disease activity | 0.361 | <0.001 |

| SLEDAI-2K versus Total Q-SLAQ | −0.046 | 0.622 |
| SLEDAI-2K versus Total Q-SLAQ with sicca | −0.084 | 0.371 |
| SLEDAI-2K versus Symptom Score | −0.028 | 0.766 |
| SLEDAI-2K versus Symptom Score with sicca | −0.042 | 0.656 |
| SLEDAI-2K versus Patient’s global disease activity | 0.086 | 0.374 |

*Correlation between symptom items

All symptom items were more frequently reported by
the physicians than the patients (table 4). The symptoms
that most of the patients assessed as being present were
fatigue (83%), arthritis/arthralgia (70%) and musculo-
skeletal symptoms (67%). When exploring the correla-
ions of single items between the patients’ and physicians’
assessments, the strongest correlations were found for
fatigue (p=0.72, p<0.001) and alopecia (p=0.71, p<0.001).
Notably, symptoms of dyspnoea/pleuritic chest pain had
the lowest correlation between patients’ and the physi-
icians’ assessments (p=0.194, p=0.039). Exploring the asso-
ciation between the SLAM question of pleuritis and one
or two of the patients’ SLAQ responses reflecting dys-
pnoea and/or chest pain did not improve the concordance
between physicians and patients regarding pulmonary/
respiratory distress.

**Comparisons between Q-SLAQ and SLAQ**

An additional set of patients (n=85) completed both the
Q-SLAQ and the SLAQ (table 5). Of these, 38 visits were
with physicians who also assessed SLAM, and 47 were
appointments without physicians, and consequently,
SLAM was not performed. Bivariate correlation between
Q-SLAQ and SLAQ were high both for the item patients
global (p=0.96) and for the two summary scores (Symptom
Score p=0.86 and total score p=0.82). In the subgroup of
participants who also met a physician (n=38), the corre-
lations between the SLAM-nolab and both the patient-
reported Q-SLAQ and the SLAQ were generally good
but in favour of the Q-SLAQ for both Symptom Score (p
0.70 vs p=0.56, p<0.001) and total score (p=0.77 vs p=0.64,
p<0.001).

**DISCUSSION**

In this study, we explored a revised and shorter version of
the Swedish SLAQ, the Q-SLAQ. Despite an easier ques-

We also explored proportional contribution of the laboratory
parameters to the total score for all 115 patients. For SLAM, laboratory measures constituted 28% (27% in high and 29% in low disease activity group). For SLEDAI-2K, ‘the laboratory fraction’ was responsible for a greater share, 63% of the total score for all (43% in the low and 82% in the high disease activity group).

In this study, we explored a revised and shorter version of
the Swedish SLAQ, the Q-SLAQ. Despite an easier ques-

When stratifying the participants into low disease activity
(≥ score 7, n=35), all the Q-SLAQ subscales confirmed a
distinct and significant difference (p>0.001) between the
two patient groups. Participants with low disease activity
had a Total Q-SLAQ median of 7 (IQR 3–13) (p<0.001)
in comparison to those with high disease activity in
whom the median was 15 (IQR 11–21). The Symptom
Score median was 7 (IQR 3–11) vs 12 (IQR 9–15), and
the Patient’s Global Disease Activity median was 2 (IQR
1–5) vs median 7 (IQR 4–8), respectively, for the high
and the low disease activity patient groups. Comparing
 correlations in the two disease groups, respectively, we
found that the correlations between patients’ and physi-
cian’s assessments were consequently higher for SLAM in
the low disease activity group, but for SLEDAI-2K, they
were better in the high disease activity group (table 3).

Patient-reported symptoms versus disease activity measures

When stratifying the participants into low disease activity
(SLAM score≤6, n=80) and high disease activity (SLAM
score≥7, n=35), all the Q-SLAQ subscales confirmed a
distinct and significant difference (p<0.001) between the
two patient groups. Participants with low disease activity
had a Total Q-SLAQ median of 7 (IQR 3–13) (p<0.001)
in comparison to those with high disease activity in
whom the median was 15 (IQR 11–21). The Symptom
Score median was 7 (IQR 3–11) vs 12 (IQR 9–15), and
the Patient’s Global Disease Activity median was 2 (IQR
1–5) vs median 7 (IQR 4–8), respectively, for the high
and the low disease activity patient groups. Comparing
correlations in the two disease groups, respectively, we
found that the correlations between patients’ and physi-
cian’s assessments were consequently higher for SLAM in
the low disease activity group, but for SLEDAI-2K, they
were better in the high disease activity group (table 3).
patients and research partners. They emphasised the importance and distress of these symptoms and how they are often neglected by the healthcare. The majority of patients with SLE with sicca symptoms seem to belong to

| Tab 1 | Frequency of positive responses per organ/item on patients’ and physicians’ assessments | Table 3 | Spearman’s correlations between patients’ Q-SLAQ and physicians’ assessments of disease activity, stratified by low SLAM scores (≤6, n=80) vs high SLAM scores (>6, n=35) |
|---|---|---|---|
| Weight loss | 20.0 | 8.7 | n.i. | 0.526 | <0.001 |
| Fatigue | 82.6 | 67.0 | n.i. | 0.718 | <0.001 |
| Fever | 21.7 | 7.0 | 4.0 | 0.397 | <0.001 |
| Lymphadenopathy | 18.3 | 6.1 | n.i. | 0.280 | 0.002 |
| Dryness eyes/mouth | 55.7 | n.i. | n.i. | – | – |
| Myalgia/myositis | 67.0 | 28.7 | 0.9 | 0.429 | <0.001 |
| Arthralgia/arthritis | 70.4 | 41.7 | 6.1 | 0.449 | <0.001 |
| Skin** | 61.7 | 19.1 | 15.9 | 0.231 | 0.014 |
| Oral ulcer***†† | 33.9 | 8.7 | 5.3 | 0.287 | 0.002 |
| Alopecia | 36.5 | 26.1 | 13.9 | 0.714 | <0.001 |
| Pleuritic chest pain | 32.5 | 4.3 | 2.6 | 0.194 | 0.039 |
| Abdominal pain | 35.7 | 7.8 | n.i. | 0.463 | <0.001 |
| Headaches | 51.3 | 27.4 | 0.9 | 0.462 | <0.001 |
| Cognitive dysfunction§†† | 66.1 | 17.4 | 1.8 | 0.365 | <0.001 |

*P ≤0.05, **P ≤0.01, ***P ≤0.001.
Q-SLAQ, Quick Systemic Lupus Activity Questionnaire; Sig, significance P; SLAM, SLE Activity Measure; SLAM-nolab, Systemic Lupus Activity Measure without laboratoryparameters; SLEDAI-2K, SLE Disease Activity Index; SLEDAI-2K-nolab, SLE Disease Activity Index without laboratory parameters.
a subset with distinct clinical and laboratory features, often considered to have a milder version of SLE. We recently demonstrated that 23% of a large SLE cohort fulfills criteria for secondary Sjögren’s syndrome, and that this subgroup is affected by a pronounced systemic inflammation. Sicca symptoms are thus both common and disturbing for patients. But, as they are usually permanent, we think that they should be regarded as a manifestation of organ damage and not disease activity. Consequently, they should be collected as a separate item and not included in this type of summary score that aims to reflect patients’ assessment of disease activity.

We omitted the item stroke, which is included in SLAM, SLEDAI-2K and the original SLAQ. Strokes, together with other vascular events, for example, myocardial infarctions and deep venous thromboses, are over-represented in SLE. In our opinion, all these items reflect damage and should not be included in a disease activity instrument. Moreover, we think that it is inappropriate and may cause unnecessary anxiety to repeatedly ask patients if they have experienced a stroke in preparation for routine clinical visits or registry registrations.

A better item response rate in comparison to our previous SLAQ study in a similar context was another strength of Q-SLAQ. We believe that the present version of the questions may be easier to understand and answer than previous versions, giving the results stronger validity. Furthermore, the internal consistency results show that the strength of the Q-SLAQ is equal to or better than the previous versions. Additionally, the results of the correlation analyses were confirmed by comparing the results of the patients with low disease activity (SLAM score≤6) and those with high disease activity (SLAM score≥7), resulting in a distinct and significant difference between the two groups. Interestingly, the best correlations between patients and physicians were observed in the group with low disease activity. Conclusions from stratified analyses must, however, be interpreted with caution since the groups are small, for example, the high disease activity group consisted of 35 patients. However, one could speculate whether patients with less symptoms have a greater chance to discuss the actual symptoms during consultation times. High disease activity in SLE often involves several organs and more extensive need to examine them. Thus, with limited consultation time, there may not be enough time to discuss patients’ perceptions of all symptoms. Furthermore, patients with high disease activity may be occupied by a few dominating symptoms, while other symptoms may be neglected unless specifically asked for. Additionally, laboratory findings, for example, urinary casts, are silent to the patients and can therefore not be addressed by the patient. Further, the large contribution of laboratory result to the total SLEDAI-2K in the low disease group (SLAM score≤6) indicates the importance to add laboratory examinations even in patients with low disease activity. Discordance between patients’ and physicians’ assessment of disease activity has previously been identified. The good correlations between patients’ and physicians’ evaluations in the ‘low-active disease group’ support the possibility that telephone or digital consultations accompanied by Q-SLAQ and laboratory tests can replace some physical visits in selected patients. Though Q-SLAQ has several advantages over the SLAQ, especially in daily clinical practice, the original SLAQ may be more useful in epidemiological or multinational studies, particularly since the SLAQ is translated and validated to many languages.

When comparing specific item correlations in the Q-SLAQ with corresponding item correlations in the Swedish SLAQ, seven items in this revised version correlated better between physicians’ and patients’ assessments. Interestingly, correlations between the specific organ items have been presented in some but not in all cultural validations of SLAQ. The results mirror discrepancies between two different perspectives and indicate gaps in the communication between patients and physicians, which in our study are most obvious regarding respiratory distress. Very weak to no correlation between the patients’ and physicians’ assessments was found for dyspnoea/chest pain. Nevertheless, the Cronbach’s alpha did not suggest that the scale needed to be altered to improve internal consistency. In the original validation of SLAQ, patients also reported pulmonary distress frequently (50%), with low associations to the physicians’ assessments on this item. This discrepancy may be explained by the fact that the patients’ assessments reflect a broader set of common symptoms than the physicians’ assessments, which is confined to clinical definitions and signs of serositis. Notably, shortness of breath,
also a symptom of heart disease, is not covered by either SLAM or SLEDAI-2K. According to our results, cardiopulmonary symptoms are relatively common in patients with SLE, and the low correlations found in the present study underscores the importance for clinicians to assess these symptoms more carefully, even early during the disease course.26 27 We believe that these findings are important and need further exploration.

SLE is a heterogeneous disease, and a complete understanding of its biological mechanisms is still lacking. Hence, evaluation of disease activity and severity of clinical manifestations is done by composite scores.8 Physicians’ assessments of disease activity in SLE and patients’ assessments of symptom distress are two perspectives that, when combined, reflect a more complete disease evaluation than if only one perspective is considered.24 Furthermore, collecting patients’ perspectives of symptoms facilitates interaction, reflection and ability to communicate symptoms and how they impact everyday life for patients.20 In the future, there is also a possibility to combine both perspectives with laboratory evaluations, where for example, measures of renal engagement are important, since they are not possible to capture by PROMs.

Further, our better correlations between Q-SLAQ and SLAM than with SLEDAI-2K demonstrate that the SLAM index includes a graded and broader range of SLE symptoms of importance to the patients, a previously discussed discrepancy.25 All these observations confirm the necessity to continue the discussion on how to differentiate disease activity from disease burden/impact and damage.23 These aspects are equally important but need different approaches and treatment actions.

We included 115 paired patient and physician assessments and we validated Q-SLAQ versus SLAQ in an additional set of 85 patients. A limited number, though our study comprises more participants than the first SLAQ study conducted by Karlson et al.5 The high response rate suggests that the questionnaire is easy to answer, which is a strength of this study. Test–retest analysis could not be performed to further validate the Q-SLAQ. This is recommended in future studies, and longitudinal studies are also needed to test how well Q-SLAQ can capture change in disease activity. Our additional data collection, with a clinical sample with and without physicians’ assessment, confirm that the Q-SLAQ present comparable data to SLAQ; however, we acknowledge that the sample is small.

We acknowledge that the original SLAQ,7 which is translated into several languages,11 15 21 22 is suitable for epidemiological studies with comparisons between countries. Nevertheless, the SLAQ is extensive, and in clinical everyday practice with frequent visits, we stress that a shorter questionnaire that covers a shorter period would be preferable. Additionally, we find that the care of today tends to include more and more digital contacts, and it is thus important to have validated patients’ assessments that we could use in a structured way. Since Q-SLAQ have the same structure and key elements as the SLAQ, we recommend Q-SLAQ rather than a completely different assessment.

To conclude, the performance of the shorter Q-SLAQ is similar to the original version of the SLAQ, demonstrating that it can be used to monitor disease activity in SLE. As we and others8 noted the substantial discrepancy between physicians’ and patients’ assessments of thoracic and respiratory pain/symptoms, further investigations of these items are clearly needed. We also explored the inclusion of sicca symptoms, based on patient suggestions, but believe that they are manifestations of damage rather than disease activity and should therefore not be part of Q-SLAQ. Overall, our results are encouraging and support the use of the Q-SLAQ in clinical care. We believe it is especially well suited in clinical situations when it is not possible to conduct physical examinations, for example, to support digital and telephone contacts, but also for registry purposes.

Author affiliations
1Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Stockholm, Sweden
2Infection/Rheumatology, Karolinska University Hospital, Stockholm, Sweden
3Department of Rheumatology and Inflammation Research, University of Gothenburg, Göteborg, Sweden
4Department of Medical Sciences, Science for Life Laboratory, Rheumatology, Uppsala University, Uppsala, Sweden
5Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden
6Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Stockholm, Sweden

Acknowledgements We are most grateful to all the patients who contributed in responding to the questions and to registered nurses Sonia Möller, Hans Kling, Marianne Petersson and Rezvan Kiani for assisting in the data collection.

Contributors All authors included in the paper fulfilled the criteria of authorship. ES: study design, data collection, statistical analyses, manuscript writing and final approval; IG, ET, AJ, DL and CS: data collection, manuscript writing and final approval; VI: statistical analysis, data collection, manuscript writing and final approval; SP: study design, statistical analysis, manuscript writing and final approval.

Funding The authors acknowledge the following financial support for the research, authorship and/or publication of this article: the Swedish Rheumatism Association, King Gustaf V’s 80-year Foundation, the Swedish Society of Medicine and the Ingegerd Johanson Donation, Swedish Research Council (2018-02533), the Region Östergötland (ALF), Stockholm County Council (ALF), the Selander Foundation, the Gustafsson foundation Karolinska Institutet and the Swedish Heart-Lung Foundation.

Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study follows the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Participants provided written informed consent to participate.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request from the corresponding author: Elisabet Svenungsson, Karolinska University Hospital, Solna, S-171 76 Stockholm, Sweden (elisabet.svenungsson@ki.se).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content
includes any translated material. BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs Elisabet Svennungsson http://orcid.org/0000-0003-3396-3244
Iva Gunnarsson http://orcid.org/0000-0002-4514-7706
Andreas Jönsen http://orcid.org/0000-0002-4418-5786
Christopher Sjöwall http://orcid.org/0000-0003-0900-2048
Susanne Pettersson http://orcid.org/0000-0001-7432-2756

REFERENCES
1 Barr SG, Zonana-Nacach A, Magder LS, et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42:2682–8.
2 Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012;64:132–7.
3 Heijke R, Björk M, Frodlund M, et al. Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus 2020;29:625–30.
4 Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015;17:183.
5 Karlson EW, Daltroy LH, Rivest C, et al. Validation of a systemic lupus activity questionnaire (SLAQ) for population studies. Lupus 2003;12:280–6.
6 Yazdany J, Yelin EH, Panapalis P, et al. Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis Rheum 2008;59:136–43.
7 Pettersson S, Svennungsson E, Gustafsson J, et al. A comparison of patients’ and physicians’ assessments of disease activity using the Swedish version of the systemic lupus activity questionnaire. Scand J Rheumatol 2007;36:474–83.
8 Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107–18.
9 Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis & Rheumatism 1992;35:630–40.
10 Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
11 Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
12 Abrahamowicz M, Fortin PR, du Berger R, et al. The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25:277–84.
13 DeVon HA, Block ME, Moyle-Wright P, et al. A psychometric toolbox for testing validity and reliability. J Nurs Scholarsh 2007;39:155–64.
14 Colton T. Statistics in medicine. 1st edn. Boston: Little, Brown, 1974.
15 Chehab G, Richter J, Sander O, et al. Validation and evaluation of the German version of the systemic lupus activity questionnaire (SLAQ). Clin Exp Rheumatol 2015;33:324–9.
16 Stefanski A-L, Tomiak C, Pleyer U, et al. The diagnosis and treatment of Sjögren’s syndrome. Disch Arztebl Int 2011;108:345–61.
17 Baer AN, Maynard JW, Shaikh F, et al. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol 2010;37:1143–9.
18 Ruacho G, Kvarnström M, Zickert A, et al. Sjögren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state. J Rheumatol 2020;47:865–75.
19 Arkema EV, Svennungsson E, Von Euler M, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis 2017;76:1544–9.
20 Aviña-Zubieta JA, Vostretsova K, De Vera MA, et al. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum 2019;49:195–201.
21 Tani C, Vagelli R, Stagnaro C, et al. Translation, cultural adaptation and validation of the systemic lupus erythematosus activity questionnaire (SLAQ) in a cohort of Italian systemic lupus erythematosus patients. Lupus 2018;27:1735–41.
22 Okamoto Y, Katsumata Y, Baba S, et al. Validation of the Japanese version of the systemic lupus activity questionnaire that includes physician-based assessments in a large observational cohort. Lupus 2016;25:486–95.
23 Elefante E, Tani C, Stagnaro C, et al. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus. Arthritis Res Ther 2020;22:241.
24 Golder V, Ooi JJY, Antony AS, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus 2018;27:501–6.
25 Dima A, Caraiola S, Delcea C, et al. Self-reported disease severity in women with systemic lupus erythematosus. Rheumatol Int 2019;39:533–9.
26 Forbes SJ, Rossides M, Weissman MH, et al. New-onset non- infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden. Arthritis Res Ther 2019;21:48.
27 Lopez Velazquez M, Highland KB. Pulmonary manifestations of systemic lupus erythematosus and Sjögren’s syndrome. Curr Opin Rheumatol 2018;30:489–94.
28 Shaw Y, Zhang C, Bradley M, et al. Acceptability and content validity of patient-reported outcome measures considered from the perspective of patients with rheumatoid arthritis. Arthritis Care Res 2020;73:510–9.
29 Chang E, Abrahamowicz M, Feland D, et al. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol 2002;55:488–97.